1d agoThe FlyBULLISH 58Product/PR
Archived explainer. For the current picture see today's FRNM page.
Why Is FREENOME INC (FRNM) Stock Down Today?
By the Top Tier Newswire AI Desk · October 12, 2026 at 1:00 PM ET · reviewed against 3 wire stories
FREENOME INC (FRNM) is down -13.18% in the latest session. Our newswire has captured 3 stories on FRNM across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Freenome Inc (FRNM) shares fell 13.18% to close at $13.70. The primary driver appears to be a combination of an upcoming data presentation and recent corporate filings, including a prospectus for the sale of shares by selling securityholders.
What Happened
Freenome announced it will present new validation data for its next-generation colorectal cancer screening test, SimpleScreen CRC, in a late-breaking oral presentation at the ACG 2026 conference. The company highlighted significant performance improvements across all subtypes of advanced precancerous lesions, which are critical for potential colorectal cancer prevention. Separately, the company filed a prospectus related to the offer and sale from time to time by selling securityholders of up to 75,188,742 shares of common stock. This secondary offering may have contributed to the selling pressure observed in the session.
What The Data Shows
The stock opened at $15.70, a 0.5% gap down from the prior close of $15.78. Intraday trading saw the stock hit a session high of $15.89 at 10:15 AM ET before sliding to a session low of $13.64 at 12:55 PM ET. Volume stood at 0.3 million shares, which is 0.5 times the three-month daily average. Freenome has a market capitalization of $1.7 billion and remains unprofitable with a trailing twelve-month EPS of -$8.84. The stock has a beta of 0.45 and trades within a 52-week range of $9.97 to $17.50. On October 12, 2026, the stock printed four fresh 52-week highs and 26 fresh 52-week lows. Recent analyst activity includes Guggenheim initiating coverage with a Buy rating and a $21 price target. Additionally, unconfirmed analyst comments circulated among traders suggesting that Carelon Healthcare Services updated clinical guideline reimbursements to include Freenome’s SimpleScreen.
What To Watch
Investors will monitor the late-breaking oral presentation at ACG 2026 for the new validation data on SimpleScreen CRC. The impact of the secondary share offering on the stock price will also be a key factor to observe in the coming sessions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
FRNM by the numbers
Last: $13.70Session: -13.18%Coverage: 3 stories / 3 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $1.7B52w: $9.97 to $17.50
The headlines behind the move
1d agoGlobeNewswireBULLISH 63Product/PR
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of...
1d agoBusiness InsiderBULLISH 63Product/PR
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on FRNM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier FRNM move explainers: 2026-10-12